A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.

MLA

Gasi Tandefelt, Delila, et al. “A 36-Gene Signature Predicts Clinical Progression in a Subgroup of ERG-Positive Prostate Cancers.” European Urology, vol. 64, no. 6, Dec. 2013, pp. 941–50. EBSCOhost, https://doi.org/10.1016/j.eururo.2013.02.039.

APA

Gasi Tandefelt, D., Boormans, J. L., van der Korput, H. A., Jenster, G. W., & Trapman, J. (2013). A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. European Urology, 64(6), 941–950. https://doi.org/10.1016/j.eururo.2013.02.039

Chicago

Gasi Tandefelt, Delila, Joost L Boormans, Hetty A van der Korput, Guido W Jenster, and Jan Trapman. 2013. “A 36-Gene Signature Predicts Clinical Progression in a Subgroup of ERG-Positive Prostate Cancers.” European Urology 64 (6): 941–50. doi:10.1016/j.eururo.2013.02.039.